|
|
 Previous Article | Table of Contents | Next Article 
Human thrombopoietin levels are high when thrombocytopenia is due to
megakaryocyte deficiency and low when due to increased platelet destruction
RV Emmons, DM Reid, RL Cohen, G Meng, NS Young, CE Dunbar and NR Shulman
Hematology Branch, NHLBI, NIH, Bethesda, MD 20892, USA.
Thrombopoietin (TPO), the ligand for c-mpl, stimulates proliferation of
committed megakaryocytic progenitors and induces maturation of
megakaryocytes. To better understand factors regulating TPO levels, we
measured blood levels of TPO in patients with impaired platelet production
due to aplastic anemia (AA) and with platelet destructive disorders,
including idiopathic thrombocytopenic purpura (ITP), posttransfusion
purpura (PTP), drug purpura (DP), and X-linked thrombocytopenia (XLTP). The
TPO receptor capture enzyme immunoassay (EIA) used had a detection limit of
integral of approximately-150 to 200 pg/mL. TPO was undetectable in 88 of
89 normal individuals. Eighteen of 19 patients with AA and a mean platelet
count (MPC) of 18,000/microliters (2,000 to 61,000/microliters) had
markedly elevated TPO levels (mean, 1,467 pg/mL; range, 597 to 3,834
pg/mL). Eight AA patients who responded to immunosuppressive therapy with
their MPC increasing to 140,000/microliters (92,000 to 175,000/microliters)
had substantial decreases in TPO (mean, 440 pg/mL; range, 193 to 771
pg/mL). Initial TPO levels did not differ significantly between responders
and nonresponders. In contrast, all 21 patients with ITP and an MPC of
16,000/microliters (1,000 to 51,000 /microliters) had undetectable TPO
levels, as did 6 patients with acute PTP or DP and 2 patients with XLTP.
Megakaryocyte mass, reflected in the rate of platelet production, appears
to be the major determinant of TPO levels in thrombocytopenic patients
rather than circulating platelet levels per se. Measurement of serum TPO
may be useful in differentiating thrombocytopenias due to peripheral
destruction from those due to thrombopoietic failure.
Volume 87,
Issue 10,
pp. 4068-4071,
05/15/1996
Copyright © 1996 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. A. Saxonhouse and M. C. Sola-Visner
Thrombocytopenia in the Neonatal Intensive Care Unit
NeoReviews,
September 1, 2009;
10(9):
e435 - e445.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. Bussel, D. J. Kuter, V. Pullarkat, R. M. Lyons, M. Guo, and J. L. Nichol
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
Blood,
March 5, 2009;
113(10):
2161 - 2171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tiedt, J. Coers, S. Ziegler, A. Wiestner, H. Hao-Shen, C. Bornmann, J. Schenkel, S. Karakhanova, F. J. de Sauvage, C. W. Jackson, et al.
Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes
Blood,
February 19, 2009;
113(8):
1768 - 1777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Gernsheimer
Chronic Idiopathic Thrombocytopenic Purpura: Mechanisms of Pathogenesis
Oncologist,
January 1, 2009;
14(1):
12 - 21.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. George and D. R. Terrell
Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia
Haematologica,
October 1, 2008;
93(10):
1445 - 1449.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. Bussel, G. Cheng, M. N. Saleh, B. Psaila, L. Kovaleva, B. Meddeb, J. Kloczko, H. Hassani, B. Mayer, N. L. Stone, et al.
Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura
N. Engl. J. Med.,
November 29, 2007;
357(22):
2237 - 2247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Schwartz
Immune Thrombocytopenic Purpura -- From Agony to Agonist
N. Engl. J. Med.,
November 29, 2007;
357(22):
2299 - 2301.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Lupia, O. Bosco, S. Bergerone, A. E. Dondi, A. Goffi, E. Oliaro, M. Cordero, L. Del Sorbo, G. Trevi, and G. Montrucchio
Thrombopoietin Contributes to Enhanced Platelet Activation in Patients With Unstable Angina
J. Am. Coll. Cardiol.,
December 5, 2006;
48(11):
2195 - 2203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. Bussel, D. J. Kuter, J. N. George, R. McMillan, L. M. Aledort, G. T. Conklin, A. E. Lichtin, R. M. Lyons, J. Nieva, J. S. Wasser, et al.
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
N. Engl. J. Med.,
October 19, 2006;
355(16):
1672 - 1681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Corazza, C. Hermans, S. D'Hondt, A. Ferster, A. Kentos, Y. Benoit, and E. Sariban
Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia
Blood,
March 15, 2006;
107(6):
2525 - 2530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. C. Haznedaroglu, H. Goker, M. Turgut, Y. Buyukasik, and M. Benekli
Thrombopoietin as a Drug: Biologic Expectations, Clinical Realities, and Future Directions
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2002;
8(3):
193 - 212.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W Fureder, U Firbas, J L Nichol, J Pistillo, S Winkler, H Hiesberger, W R Sperr, J Smolen, and G Schett
Serum thrombopoietin levels and anti-thrombopoietin antibodies in systemic lupus erythematosus
Lupus,
April 1, 2002;
11(4):
221 - 226.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. B. Cines and V. S. Blanchette
Immune Thrombocytopenic Purpura
N. Engl. J. Med.,
March 28, 2002;
346(13):
995 - 1008.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kaser, G. Brandacher, W. Steurer, S. Kaser, F. A. Offner, H. Zoller, I. Theurl, W. Widder, C. Molnar, O. Ludwiczek, et al.
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis
Blood,
November 1, 2001;
98(9):
2720 - 2725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Gouin-Thibault, B. Cassinat, C. Chomienne, J.-D. Rain, Y. Najean, and M.-H. Schlageter
Is the Thrombopoietin Assay Useful for Differential Diagnosis of Thrombocytopenia? Analysis of a Cohort of 160 Patients with Thrombocytopenia and Defined Platelet Life Span
Clin. Chem.,
September 1, 2001;
47(9):
1660 - 1665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ando, Y. Iwamoto, A. Suda, K. Tsuchiya, and H. Nihei
New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels
Blood,
February 15, 2001;
97(4):
915 - 921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Drachman, G. P. Jarvik, and M. G. Mehaffey
Autosomal dominant thrombocytopenia: incomplete megakaryocyte differentiation and linkage to human chromosome 10
Blood,
July 1, 2000;
96(1):
118 - 125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. E. Albert, Y. G. Meng, P. Simms, R. L. Cohen, and R. H. Phibbs
Thrombopoietin in the Thrombocytopenic Term and Preterm Newborn
Pediatrics,
June 1, 2000;
105(6):
1286 - 1291.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. A. Schiffer, K. Miller, R. A. Larson, P. C. Amrein, J. H. Antin, V. J. Zani, and R. M. Stone
A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia
Blood,
April 15, 2000;
95(8):
2530 - 2535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-W. Chu, J. Korb, and K. M. Sakamoto
Idiopathic Thrombocytopenic Purpura
Pediatr. Rev.,
March 1, 2000;
21(3):
95 - 104.
[Full Text]
|
|
|
|
|
|
|
M. Chang, J. X. Qian, S. m. Lee, J. Joubran, G. Fernandez, J. Nichols, A. Knoppel, and J. S. Buzby
Tissue Uptake of Circulating Thrombopoietin Is Increased in Immune-Mediated Compared With Irradiated Thrombocytopenic Mice
Blood,
April 15, 1999;
93(8):
2515 - 2524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. van der Loo and J. F. Martin
A Role for Changes in Platelet Production in the Cause of Acute Coronary Syndromes
Arterioscler Thromb Vasc Biol,
March 1, 1999;
19(3):
672 - 679.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Colarizi, P. Fiorucci, M. Roggini, and P. Papoff
Circulating Thrombopoietin Levels in a Neonate With Osteopetrosis
Pediatrics,
March 1, 1999;
103(3):
700 - 701.
[Full Text]
|
|
|
|
|
|
|
N. Ghilardi, A. Wiestner, and R. C. Skoda
Thrombopoietin Production Is Inhibited by a Translational Mechanism
Blood,
December 1, 1998;
92(11):
4023 - 4030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Poujol, D. T.-L. Roux, P. Tropel, V. Roullot, A. Nurden, G. Marguerie, and P. Nurden
Ultrastructural Analysis of Bone Marrow Hematopoiesis in Mice Transgenic for the Thymidine Kinase Gene Driven by the alpha IIb Promoter
Blood,
September 15, 1998;
92(6):
2012 - 2023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Moliterno, W. D. Hankins, and J. L. Spivak
Impaired Expression of the Thrombopoietin Receptor by Platelets from Patients with Polycythemia Vera
N. Engl. J. Med.,
February 26, 1998;
338(9):
572 - 580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Frey, S. Rafii, M. Teterson, D. Eaton, R. G. Crystal, and M. A.S. Moore
Adenovector-Mediated Expression of Human Thrombopoietin cDNA in Immune-Compromised Mice: Insights into the Pathophysiology of Osteomyelofibrosis
J. Immunol.,
January 15, 1998;
160(2):
691 - 699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Ishida, T. Ito, and S.-i. Kuriya
Effects of C-Mpl Ligand on Cytoplasmic Maturation of Murine Megakaryocytes and on Platelet Production
J. Histochem. Cytochem.,
January 1, 1998;
46(1):
49 - 58.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Y. Horikawa, I. Matsumura, K. Hashimoto, M. Shiraga, S. Kosugi, S. Tadokoro, T. Kato, H. Miyazaki, Y. Tomiyama, Y. Kurata, et al.
Markedly Reduced Expression of Platelet c-mpl Receptor in Essential Thrombocythemia
Blood,
November 15, 1997;
90(10):
4031 - 4038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Abraham and R. L. Basser
Megakaryocyte Growth and Development Factor: A Review of Early Clinical Studies
Oncologist,
October 1, 1997;
2(5):
311 - 318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Neelis, S. C.C. Hartong, T. Egeland, G. R. Thomas, D. L. Eaton, and G. Wagemaker
The Efficacy of Single-Dose Administration of Thrombopoietin With Coadministration of Either Granulocyte/Macrophage or Granulocyte Colony-Stimulating Factor in Myelosuppressed Rhesus Monkeys
Blood,
October 1, 1997;
90(7):
2565 - 2573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Shivdasani, P. Fielder, G.-A. Keller, S. H. Orkin, and F. J. de Sauvage
Regulation of the Serum Concentration of Thrombopoietin in Thrombocytopenic NF-E2 Knockout Mice
Blood,
September 1, 1997;
90(5):
1821 - 1827.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Young and J. Maciejewski
The Pathophysiology of Acquired Aplastic Anemia
N. Engl. J. Med.,
May 8, 1997;
336(19):
1365 - 1372.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. C. Broudy, N. L. Lin, D. F. Sabath, T. Papayannopoulou, and K. Kaushansky
Human Platelets Display High-Affinity Receptors for Thrombopoietin
Blood,
March 15, 1997;
89(6):
1896 - 1904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Arnold, N. C. Daw, P. E. Stenberg, D. Jayawardene, D. K. Srivastava, and C. W. Jackson
A Single Injection of Pegylated Murine Megakaryocyte Growth and Development Factor (MGDF ) Into Mice Is Sufficient to Produce a Profound Stimulation of Megakaryocyte Frequency, Size, and Ploidization
Blood,
February 1, 1997;
89(3):
823 - 833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
